Want to see SLGL full AI Analyst Report?
Top Page
Sol-Gel Technologies
(NASDAQ:SLGL)
Select Model
Select Model
Rating:60Neutral
Price Target:
$83.00
▲(1.57% Upside)
Action:Reiterated
Date:10/07/26
The score is primarily supported by strong technical momentum (price above key moving averages with positive MACD). Offsetting this, financial performance remains only moderate due to ongoing net/operating losses and a reduced equity cushion despite improved 2025 revenue and cash flow. Valuation also weighs on the score because the negative P/E reflects unprofitability and there is no dividend yield.
Positive Factors
Commercial dermatology platform
An established dermatology platform with marketed prescription products provides an existing commercial foundation while supporting future topical therapies. The combination of product sales and specialized formulation capabilities can improve customer familiarity, leverage development know-how, and create a durable base for pipeline expansion.
Negative Factors
Sharp revenue volatility and ongoing losses
The steep quarterly revenue decline and return to a net loss show that reported earnings remain highly volatile and are not yet supported by a consistently profitable commercial base. Continued dependence on uneven revenue sources could constrain reinvestment and make durable cash generation difficult to establish.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial dermatology platform
An established dermatology platform with marketed prescription products provides an existing commercial foundation while supporting future topical therapies. The combination of product sales and specialized formulation capabilities can improve customer familiarity, leverage development know-how, and create a durable base for pipeline expansion.
Read all positive factors
Sol-Gel Technologies (SLGL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$234.97M
Dividend YieldN/A
Average Volume (3M)54.21K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth-92.50%
EPS Growth-361.11%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.97
Shares Outstanding3,273,999
10 Day Avg. Volume37,654
30 Day Avg. Volume54,213
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.15
Price to Sales (P/S)6.06
P/FCF Ratio426.90
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue29.78
Enterprise Value/Gross Profit81.79
Enterprise Value/Ebitda-59.32
Forecast
1Y Price Target
$152.50Price Target Upside86.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-8.88
Revenue Forecast (FY)$708.00K
Sol-Gel Technologies Business Overview & Revenue Model
Company Description
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation tec...
How the Company Makes Money
Sol-Gel makes money primarily from commercial sales of its dermatology products and from collaboration-related income tied to partnered commercialization. Revenue is generated through: (1) Product sales: income from selling its marketed prescripti...
Sol-Gel Technologies Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.56M | 19.39M | 11.54M | 1.55M | 3.88M | 31.27M |
| Gross Profit | 2.39M | 19.39M | 11.54M | 1.55M | -8.80M | 10.89M |
| EBITDA | -3.29M | -7.43M | -11.78M | -28.96M | -15.68M | 3.84M |
| Net Income | -14.91M | -6.13M | -10.58M | -27.24M | -14.92M | 3.22M |
Balance Sheet | ||||||
| Total Assets | 42.01M | 29.92M | 35.85M | 45.29M | 46.63M | 69.19M |
| Cash, Cash Equivalents and Short-Term Investments | 30.47M | 24.00M | 23.93M | 38.00M | 33.63M | 43.24M |
| Total Debt | 1.39M | 991.00K | 1.31M | 1.65M | 772.00K | 1.59M |
| Total Liabilities | 7.10M | 7.11M | 7.00M | 6.64M | 4.42M | 13.60M |
| Stockholders Equity | 34.90M | 22.81M | 28.85M | 38.64M | 42.21M | 55.59M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 275.00K | -13.89M | -17.86M | -9.65M | -7.83M |
| Operating Cash Flow | 0.00 | 322.00K | -13.89M | -17.73M | -9.48M | -7.69M |
| Investing Cash Flow | 0.00 | -8.58M | 26.69M | -9.74M | 1.70M | 19.87M |
| Financing Cash Flow | 0.00 | 6.00K | 0.00 | 21.81M | 15.00K | 837.00K |
Sol-Gel Technologies Technical Analysis
Negative
81.72
Price Trends
73.33
Negative
74.47
Negative
72.69
Negative
Market Momentum
0.67
Negative
51.98
Neutral
42.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLGL, the sentiment is Negative. The current price of 81.72 is above the 20-day moving average (MA) of 67.74, above the 50-day MA of 73.33, and above the 200-day MA of 72.69, indicating a neutral trend. The MACD of 0.67 indicates Negative momentum. The RSI at 51.98 is Neutral, neither overbought nor oversold. The STOCH value of 42.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLGL.
Sol-Gel Technologies Risk Analysis
Sol-Gel Technologies disclosed 72 risk factors in its most recent earnings report. Sol-Gel Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sol-Gel Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $234.97M | -12.73 | -44.05% | ― | -92.50% | -361.11% | |
56 Neutral | $599.17M | -11.71 | -43.57% | ― | -66.63% | 57.89% | |
54 Neutral | $348.96M | -0.72 | 187.62% | ― | -8.79% | -195.46% | |
53 Neutral | $480.43M | -5.13 | -23.64% | ― | -76.20% | 52.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $110.28M | -2.22 | 271.76% | ― | -60.77% | 57.26% | |
45 Neutral | $37.78M | -0.40 | -63.65% | ― | -59.84% | -5.97% |
* Healthcare Sector Average
SLGL
Sol-Gel Technologies
71.77
31.82
79.65%
IMDX
Insight Molecular Diagnostics
3.37
-0.53
-13.59%
OVID
Ovid Therapeutics
2.46
0.88
55.70%
STTK
Shattuck Labs
5.97
4.13
224.46%
SRZN
Surrozen
29.69
15.87
114.83%
MGX
Metagenomi, Inc.
1.00
-1.85
-64.91%
Sol-Gel Technologies Corporate Events
Sol-Gel Technologies Sets November Shareholder Meeting to Cement Leadership and Expand Capital Base
Oct 6, 2026
Sol-Gel Technologies has called its 2026 annual meeting of shareholders for November 17, 2026, in New York, asking investors to approve the reappointment of Kesselman Kesselman as its independent auditor for 2026 and to re-elect several directors...
Sol-Gel Technologies Sets October 14 KOL Investor Day for SGT-610
Sep 30, 2026
Sol-Gel Technologies Ltd. is a specialized dermatology company focused on innovative therapies for rare and serious skin diseases. Its lead investigational candidate, SGT-610 (patidegib gel 2%), is a Phase 3, orphan- and breakthrough-designated to...
Sol-Gel Technologies Reaches Last-Patient Milestone in Phase 3 Gorlin Syndrome Trial
Sep 17, 2026
On September 17, 2026, Sol-Gel Technologies reported that the last patient completed the final scheduled visit in its pivotal Phase 3 trial of SGT-610 for Gorlin syndrome. This milestone concludes the treatment and follow-up phase for 113 enrolled...
Sol-Gel Technologies Posts Q2 Loss as Pivotal Gorlin Syndrome Trial Advances Toward Late-2026 Readout
Aug 20, 2026
On August 20, 2026, Sol-Gel Technologies reported its second-quarter results for the period ended June 30, 2026, highlighting steady execution across its clinical programs despite a sharp year-on-year revenue decline. The company posted revenue of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.